已收盤 04-02 16:00:00 美东时间
0.000
0.00%
Amesite enters electronic transactions trading partner agreement with leading homecare technology platform; NurseMagic enables HIPAA-compliant EVV exchange for providers Amesite entered an Electronic Transactions Trading Partner Agreement with a homecare technology platform company to support HIPAA-
03-26 22:32
Amesite Inc. (Nasdaq: AMST) has entered into a HIPAA-compliant Electronic Transactions Trading Partner Agreement with a leading homecare technology platform company, enabling secure exchange of electronic visit verification (EVV) transactions. This integration allows NurseMagic™, Amesite's AI-native platform, to stream
03-26 14:30
<p>Amesite, Inc. (NASDAQ: AMST) 宣布其AI驱动的NurseMagic™平台被Nurse.org评为“最佳护理奖”决赛入围者。该平台旨在帮助后急性护理环境中的临床医生更高效地完成文档和管理任务,从而减少行政工作,使临床医生有更多时间直接照顾患者。自2025年初推出以来,NurseMagic™迅速扩展到全美50个州以及多个国际地区,并通过多个产品升级实现了显著的收入增长。预计后急性护理市场到2035年将超过8000亿美元,Amesite的目标是通过其AI原生EMR进一步扩大市场份额。</p>
03-04 11:30
Gainers FAT Brands (NASDAQ:FATBB) stock rose 58.0% to $1.21 during Tuesday's r...
02-04 01:05
Gainers Autozi Internet Tech (NASDAQ:AZI) shares rose 81.6% to $4.54 during Mo...
2025-12-22 20:05
Shares of Clearwater Analytics Holdings, Inc. (NYSE:CWAN) rose sharply in pre-m...
2025-12-22 19:00
Amesite Inc. launched NurseMagic™ EMR, expanding its AI-driven platform into post-acute care infrastructure. Following strong revenue growth and enterprise adoption, the new EMR supports legacy systems or full replacements, offering flexibility to customers. Revenue increased 2.4x after Teams+ launch and climbed 82% with the Enterprise tier, priced based on patient census. The U.S. post-acute care market, valued at $470B, is growing due to aging ...
2025-12-19 11:30
Amesite Inc. (NASDAQ:AMST), a leading developer of AI-powered enterprise solutions, announces a 69% QoQ increase in revenue even as it reduced its spending. Amesite also reported expanding its customer base and offerings
2025-10-30 18:42
Gainers Jinxin Technology Holding (NASDAQ:NAMI) shares rose 12.2% to $1.01 dur...
2025-10-20 20:08
SLXN: 50% | Silexion Highlights Preclinical Data Of SIL204 Supporting Dual-Route Treatment Strategy With Phase 2/3 Trial On Track For 2026 VNCE: 242% | Vince Holding Q2 Adj. EPS $0.38 Beats $(0.10)
2025-09-11 19:26